CID Equity Partners
VC Fund
Indianapolis, United States
CID Equity Partners is a VC fund in Indianapolis focused on Software and Health Care. CID Equity has financed the growth plans of emerging technology companies, funded management buyouts.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CID Equity Partners invests in
SoftwareHealth CareAppsSaaSDental
Stages CID Equity Partners invests in
Series BSeries AFunding RoundSeries CSeries D
Countries CID Equity Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Software 3 (25%)
- Health Care 2 (17%)
- Apps 1 (8%)
- SaaS 1 (8%)
- Dental 1 (8%)
Stage
- Series B 3 (25%)
- Series A 2 (17%)
- Funding Round 2 (17%)
- Series C 1 (8%)
- Series D 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Randall S. Glein
principal investing positions
|
principal investing positions | Total investments: 0 | Find email | |
Randy Glein
principal investing positions
|
principal investing positions | Total investments: 29 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Atlantis has designed a software system known as the Virtual Abutment Design (VAD) system. VAD allows their technicians to design abutments with a certainty and precision previously unknown to implant dentistry.The following is an overview of the Atlantis VAD and titanium machining process. The same process is followed by their technicians forsingle and multiple unit cases. | $9.8M / Series D / May 22, 2007 | ||
| SPS Commerce gives retail trading partners an intelligent way to manage and fulfill orders. Based on a multi-tenant, SaaS model, SPS' services deliver greater functionality, integration and reliability with less cost and risk than traditional software. | $7.5M / May 09, 2007 | ||
| Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancersof the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana. | $30M / Nov 13, 2006 | ||
| AGEIA Technologies, Inc. develops hardware-accelerated physics for PC games. It offers PhysX, a physics engine and processor that bridges the gap between static virtual worlds and responsive unscripted physical reality. The company’s PhysX processor also provides hardcore gamers and gaming enthusiasts with simulations of collisions, explosions,complex jointed geometries, fabrics, dense smoke and liquids, multiple objects and particles, and other physical effects. It also offers a software development kit to simplify physics programming and gaming consoles. AGEIA Technologies was founded in 2002 and is based in Santa Clara, California with an additional office in Mountain View, California. As of February 10, 2008, AGEIA Technologies, Inc. operates as a subsidiary of NVIDIA Corporation. | $27.5M / Series C / Oct 03, 2005 | ||
| AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venturecapitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine. | $18M / Series B / Feb 23, 2005 | ||
| AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venturecapitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine. | $2.8M / Series A / Feb 10, 2003 | ||
| SPS Commerce gives retail trading partners an intelligent way to manage and fulfill orders. Based on a multi-tenant, SaaS model, SPS' services deliver greater functionality, integration and reliability with less cost and risk than traditional software. | Nov 14, 2002 | ||
| Intersymbol Communications, Inc. develops and manufactures high-speed physical layer components for next generation broadband networking systems. Intersymbol's innovative products enhance the bandwidth and reach while simultaneously reducing the power consumption of broadband networks. This results in a dramatic reduction in deployment costfor next generation network providers. | $5M / Series A / Sep 30, 2002 | ||
| SmartSignal Corporation provides Predictive Diagnostic software and services. Its solutions include EPI*Center, CycleWatch, SHIELD, xConnector, and PlantAPS. The company offers equipment and process failure detection and diagnosis. SmartSignal has strategic partnerships with OSIsoft, Accenture, Microsoft, and MRG (Management Resources Group, Inc).The company caters to power generation and oil and gas sectors. Its clientele include BP, Caterpillar, Duke Energy, GDF Suez, Invenergy, Scottish and Southern, and TransAlta. The company was founded in 1999 and is based in Lisle, Illinois. | $12M / Series B / Jan 02, 2002 | ||
| fourthchannel is a provider of hosted e-business solutions that enable manufacturers and distributors to sell complex products via the Internet. fourthchannel's integrated catalog, order management, configuration and transaction capabilities enhance relationships between suppliers, distributors and their customers. With fourthchannel'sproven platform companies can expand and manage their selling channels, participate fully in e-marketplaces, and develop private exchanges with collaborative capabilities. | $20M / Series B / Apr 07, 2000 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
117,441 investors
Software Investors
57,331 investors
Health Care Investors
48,627 investors
SaaS VC Funds
71,923 investors
Software VC Funds
36,593 investors
Health Care VC Funds
36,465 investors
SaaS Investors in United States
54,056 investors
Software Angel Investors
20,738 investors
Health Care Investors in United States
23,845 investors
FAQ
What does CID Equity Partners invest in?
CID Equity Partners invests primarily in Software, Health Care and Apps startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CID Equity Partners?
Public channels for CID Equity Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CID Equity Partners?
The team at CID Equity Partners includes Randall S. Glein (principal investing positions) and Randy Glein (principal investing positions). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
